Comparative Pharmacology
Head-to-head clinical analysis: IMFINZI versus TECENTRIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMFINZI versus TECENTRIQ.
IMFINZI vs TECENTRIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Programmed cell death ligand 1 (PD-L1) inhibitor; binds to PD-L1 on tumor cells and immune cells, blocking interaction with PD-1 and B7.1 receptors on T cells, thereby restoring anti-tumor immune response.
Atezolizumab is a humanized monoclonal IgG1 antibody that binds to PD-L1, blocking its interaction with PD-1 and CD80 receptors, thereby reversing PD-L1-mediated inhibition of T-cell activation and restoring anti-tumor immune responses.
10 mg/kg intravenously every 2 weeks for up to 12 months or until disease progression or unacceptable toxicity.
800 mg intravenously every 2 weeks; or 1200 mg intravenously every 3 weeks; or 1680 mg intravenously every 4 weeks.
None Documented
None Documented
The terminal elimination half-life (t1/2) is approximately 21 days (range: 14–27 days) in patients with advanced solid tumors. This long half-life supports a fixed dosing interval of every 2 or 4 weeks.
Terminal elimination half-life is approximately 27 days (range: 20–35 days). This long half-life supports every-3-week dosing and reflects slow clearance typical of IgG1 antibodies.
Durvalumab is eliminated primarily through catabolism into small peptides and amino acids. No significant renal or biliary excretion of intact drug occurs. Based on population pharmacokinetic analysis, the mean clearance (CL) is 0.235 L/day in patients with typical body weight (70 kg).
Tecentriq (atezolizumab) is a monoclonal antibody; elimination occurs via intracellular catabolism into amino acids. No renal or biliary/fecal excretion of intact drug. 0% unchanged in urine or feces.
Category C
Category C
PD-L1 Inhibitor
Antineoplastic, PD-L1 Inhibitor